SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mr. Park who wrote (25135)12/9/1998 8:51:00 PM
From: DO$Kapital  Read Replies (1) of 119973
 
From DECEMBER 2ND:

<<<ANN ARBOR, Mich., Dec 2 (Reuters) - Aastrom Biosciences Inc. said
Wednesday that it started a pivotal clinical trial with its
AastromReplicell Cell Production System to provide an alternative
method of cell collection for cancer patients requiring an autologous stem
cell transplant.

Results from an earlier trial, completed under an investigational device
exemption from the U.S. Food and Drug Administration, were positive,
the company said.

Chief Executive Douglas Armstrong said, "The pivotal trial represents
an extension of the earlier trial ... We believe the subsequent trial results
will further demonstrate the clinical utility of the AastromReplicell
System."

AastromReplicell is designed to produce cells useful in a broad range of
therapies. Stem cell transplants are commonly used to treat patients
with cancer or other diseases who have undergone extensive
chemotherapy or radiation treatments.

These treatments can damage or destroy the patient's bone marrow and
blood and immune system cells. As a result, these patients sometimes
need a stem cell transplant to restore their vital cells and tissues,
Aastrom said.

The AastromReplicell is an automated clinical system for producing
hard-to-collect therapeutic cells from small starting quantities. >>>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News